{
    "id": 5299,
    "name": "endometrial clear cell adenocarcinoma",
    "source": "DOID",
    "definition": "An endometrial adenocarcinoma that is characterized by the presence of cells with clear cytoplasm. [url:https\\://www.ncbi.nlm.nih.gov/pubmed/24817975]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:5299",
    "evidence": [
        {
            "id": 11605,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with clear cell endometrial cancer treated with ONC201 (TIC-10) demonstrated some reduction in lesion size (>30%), but also developed new lesions (PMID: 28331050).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1687,
                "therapyName": "ONC201",
                "synonyms": null
            },
            "indication": {
                "id": 5299,
                "name": "endometrial clear cell adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9666,
                    "pubMedId": 28331050,
                    "title": "First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28331050"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00492778",
            "title": "Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01396408",
            "title": "A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02065687",
            "title": "Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1381,
                    "therapyName": "Carboplatin + Metformin + Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03120624",
            "title": "VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7269,
                    "therapyName": "VSV-hIFNbeta-NIS",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03694262",
            "title": "The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) (EndoBARR)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7499,
                    "therapyName": "Atezolizumab + Bevacizumab + Rucaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03914612",
            "title": "Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2103,
                    "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04197219",
            "title": "Pembrolizumab With Axitinib in Recurrent Endometrial Cancer",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 2494,
                    "therapyName": "Axitinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        }
    ]
}